Hyperlipidaemia and cardiovascular disease

Current Opinion in Lipidology

Volumn 18, Issue 4, 2007, Pages 473-475

  Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ALPHA TOCOPHEROL; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; EDITORIAL; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTIOXIDANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; LIPOPROTEINS, LDL; MAGNETIC RESONANCE IMAGING; RISK;

EID: 34447333367     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32823bcb28     Document Type: Editorial

References (14)

1. Hartmann M, Birgelen C, Mintz GS, et al. Relation between plaque progression and low-density lipoprotein cholesterol during aging as assessed with serial long-term (≥12 months). Follow-up intravascular ultrasound of the left main coronary artery. Am J Cardiol 2006; 11:1419-1423.
2. Komatsu S, Murakawa T, Shinohe T, et al. Detection of silently ruptured plaque by coronary magnetic resonance. Int J Cardiol 2006; 113:430-431.
3. Saam T, Ma L, Cai YQ, et al. Comparison of symptomatic and asymptomatic atherosclerotic carotid plaque features with in vivo MR imaging. Radiology 2006; 240:464-472.
4. Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI: initial results. Stroke 2006; 37:818-823.
5. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomised controlled trials. Arch Intern Med 2006; 166:2307-2313.
6. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006; 17:626-630.
7. Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitors therapy. J Cardiovasc Pharmacol 1998; 31:39-45.
8. Aviram M, Rosenbalt M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23:423-433.
9. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006;17:631-636.
10. Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 2006; 98:1542-1549.
11. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of HDL-associated serumparaoxonase 1 (PON1) is essential forPON1-mediated inhibition of LDL oxidation and for stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281:7657-7665.
12. Wong J, Quinn CM, Brown AJ. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem J 2006; 400:485-491.
13. Rosenblat M, Shih D, Vaya J, et al. Paraoxonase 1 (PON 1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter, in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005; 179:69-77.
14. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON 1) is more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006; 187:74-81.